Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Authors
Bowyer, SPrithviraj, P
Lorigan, Paul C
Larkin, J
McArthur, G
Atkinson, V
Millward, M
Khou, M
Diem, S
Ramanujam, S
Kong, B
Liniker, E
Guminski, A
Parente, P
Andrews, M C
Parakh, S
Cebon, J
Long, G
Carlino, M
Klein, O
Affiliation
Rockingham General Hospital, Cooloongup, Western Australia, AustraliaIssue Date
2016-05-10
Metadata
Show full item recordAbstract
Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.Citation
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 2016, 114 (10):1084-9 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2016.107PubMed ID
27124339Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2016.107
Scopus Count
Collections
Related articles
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
- Authors: Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD
- Issue date: 2017 Dec 1
- Nivolumab plus ipilimumab in advanced melanoma.
- Authors: Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M
- Issue date: 2013 Jul 11
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
- Authors: Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI
- Issue date: 2017 Apr
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
- Authors: Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD
- Issue date: 2015 Jul
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
- Authors: Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS
- Issue date: 2016 Jul